Drug Profile

Research programme: hepatitis B virus antigen inhibitors - GlaxoSmithKline

Alternative Names: HBV antigen inhibitor series - GlaxoSmithKline

Latest Information Update: 28 Dec 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GlaxoSmithKline
Developer GSK
Class Antivirals; Small molecules
Mechanism of Action Hepatitis B surface antigen expression inhibitors; Virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Dec 2023 No recent reports of development identified for preclinical development in Hepatitis-B in United Kingdom (PO)
08 Nov 2019 Pharmacodynamics data from a preclinical trial in Hepatitis B presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com